These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 26964996)

  • 1. Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.
    Jones CR; Hatley OJ; Ungell AL; Hilgendorf C; Peters SA; Rostami-Hodjegan A
    AAPS J; 2016 May; 18(3):589-604. PubMed ID: 26964996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.
    Cho HJ; Kim JE; Kim DD; Yoon IS
    Drug Dev Ind Pharm; 2014 Aug; 40(8):989-98. PubMed ID: 23981203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of human pharmacokinetics--gut-wall metabolism.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1335-43. PubMed ID: 17910807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH; Bouchene S; Hilgendorf C; Dolgos H; Peters SA
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
    Galetin A; Hinton LK; Burt H; Obach RS; Houston JB
    Curr Drug Metab; 2007 Oct; 8(7):685-93. PubMed ID: 17979656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.
    Shen DD; Kunze KL; Thummel KE
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):99-127. PubMed ID: 10837554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.
    Peters SA; Jones CR; Ungell AL; Hatley OJ
    Clin Pharmacokinet; 2016 Jun; 55(6):673-96. PubMed ID: 26895020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models for predicting drug absorption and metabolism.
    Alqahtani S; Mohamed LA; Kaddoumi A
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1241-54. PubMed ID: 23687990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of drug metabolizing enzymes in clearance.
    Di L
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):379-93. PubMed ID: 24392841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans?
    Ritchie TJ; Macdonald SJ
    Drug Discov Today; 2014 Apr; 19(4):489-95. PubMed ID: 24462956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of intestinal first-pass drug metabolism.
    Yang J; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
    Curr Drug Metab; 2007 Oct; 8(7):676-84. PubMed ID: 17979655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the potential role of intestinal first-pass metabolism for the prediction of drug-drug interactions: the role of PBPK modeling.
    Alqahtani S; Bukhari I; Albassam A; Alenazi M
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):625-634. PubMed ID: 29806951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral bioavailability and first-pass effects.
    Kwan KC
    Drug Metab Dispos; 1997 Dec; 25(12):1329-36. PubMed ID: 9394021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.
    Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
    J Pharm Sci; 2009 Nov; 98(11):4343-53. PubMed ID: 19230019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug metabolism in the small intestine--the significance for biological availability].
    Andersen VC; Sonne J
    Ugeskr Laeger; 2000 May; 162(22):3215-9. PubMed ID: 10850220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.